Clinical Report: Pediatric Hypertension Assessment Using Clinical vs Claims Data
Overview
This study analyzed over 3.7 million pediatric patients to compare hypertension identification via clinical blood pressure measurements and administrative claims data. Findings reveal that claims data substantially under-captures pediatric hypertension cases but may indicate more severe disease.
Background
Pediatric hypertension is a growing public health concern linked to adult cardiovascular disease and associated comorbidities. Elevated blood pressure in childhood predicts adult hypertension, with prevalence estimates around 2-4% for hypertension and 16.3% for elevated BP in children aged 10-17. Real-world data sources like electronic health records (EHRs) and administrative claims are increasingly used to identify and study pediatric hypertension, but their accuracy and completeness vary. The FDA’s Sentinel System integrates both data types, providing a unique opportunity to compare clinical and claims-based hypertension identification.
Data Highlights
Measure
Children (3-12 yrs)
Teens (13-17 yrs)
Total patients with ≥3 BP measurements
781,722
551,246
Clinical hypertension prevalence
70,315 (9%)
47,928 (8.7%)
Clinical elevated, nonhypertensive BP
22,465 (2.8%)
60,952 (11%)
Claims-based hypertension identified
3,246
7,293
Claims among clinically hypertensive
2.2%
7.3%
Follow-up duration
Up to 3 years
Up to 3 years
Key Findings
Among children and teens with multiple BP measurements, approximately 9% and 8.7% met clinical hypertension criteria, respectively.
Claims data identified far fewer hypertensive patients (3,246 children; 7,293 teens) compared to clinical definitions.
Only 2.2% of clinically hypertensive children and 7.3% of clinically hypertensive teens had corresponding hypertension claims, indicating poor claims capture.
Patients identified via claims data exhibited more severe disease profiles and higher all-cause mortality during follow-up.
Claims-based identification may be biased toward advanced hypertension stages, limiting utility for early disease studies.
Racial and ethnic disparities in pediatric hypertension prevalence were acknowledged but not detailed in this analysis.
Clinical Implications
Clinicians and researchers should recognize that administrative claims data substantially under-represent pediatric hypertension cases and may preferentially capture more severe disease. For comprehensive surveillance and early identification, reliance on clinical BP measurements from EHRs is preferable. Understanding coding practices and data source limitations is critical when designing pediatric hypertension studies using real-world data.
Conclusion
This large-scale comparison demonstrates that clinical BP measurements identify a broader pediatric hypertensive population than claims data, which under-captures cases but may indicate greater disease severity. Integrating both data sources can enhance pediatric hypertension research and surveillance.
References
Kaelber et al. 2018 -- Identification of Pediatric Hypertension in Ambulatory EHR Databases
American Academy of Pediatrics 2017 -- Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents
FDA Sentinel System -- Real-World Evidence Program
